NASDAQ:ZLABZai Lab Stock Price, Forecast & News

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZLAB shares have increased by 61.8% and is now trading at $81.10. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zai Lab.

Zai Lab Ltd (NASDAQ:ZLAB) announced its quarterly earnings results on Thursday, March, 19th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.05. The company earned $4.65 million during the quarter. View Zai Lab's earnings history.

7 Wall Street analysts have issued 1 year price targets for Zai Lab's shares. Their forecasts range from $36.54 to $84.00. On average, they anticipate Zai Lab's share price to reach $57.31 in the next twelve months. This suggests that the stock has a possible downside of 29.3%. View analysts' price targets for Zai Lab.

Media coverage about ZLAB stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zai Lab earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the stock's share price in the next few days. View the latest news about Zai Lab.

Some companies that are related to Zai Lab include Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Mylan (MYL) and ACADIA Pharmaceuticals (ACAD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Inseego (INSG), InVitae (NVTA), Baozun (BZUN), Fulgent Genetics (FLGT), Intellia Therapeutics (NTLA), Beigene (BGNE), Marvell Technology Group (MRVL) and Niu Technologies (NIU).

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZLAB stock can currently be purchased for approximately $81.10.

Zai Lab has a market capitalization of $4.71 billion and generates $12.98 million in revenue each year. The company earns $-195,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. Zai Lab employs 309 workers across the globe.

The official website for Zai Lab is www.zailaboratory.com.

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]